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An area of research that has been recently gaining attention is the relationship between cancer stem cell (CSC)
biology and chemo-resistance in colon cancer patients. It is well recognized that tumor initiation, growth, invasion
and metastasis are promoted by CSCs. An important reason for the widespread interest in the CSC model is that it
can comprehensibly explain essential and poorly understood clinical events, such as therapy resistance, minimal
residual disease, and tumor recurrence. This review discusses the recent advances in colon cancer stem cell research,
the genes responsible for CSC chemoresistance, and new therapies against CSCs.
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Colorectal cancer (CRC) is the third leading cause of
cancer death worldwide, and the 5-year relative survival
rate is only 8% [1] despite diagnostic and therapeutic
advances. Tumor recurrence and metastasis are two crit-
ical survival-influencing factors of CRC. Many researchers
have observed that some cancer cells (such as breast can-
cer, colon cancer, etc.) acquire the characteristics of cancer
stem cells through the epithelial-mesenchymal transition
(EMT) [2-4], which is responsible for promoting the inva-
sion of CRC cells into the basement membrane and the
surrounding microenvironment, including the lymph and
blood vascular systems, a phenomenon that contributes to
the intra- and/or extravasation of the tumor [5,6].
As a result of the EMT, the epithelial cells in a tumor,
which normally interact with the basement membrane
via their basal surface, are polarized, causing multiple
biochemical changes, including enhanced migratory cap-
acity, invasiveness, elevated resistance to apoptosis, and
greatly increased production of extracellular matrix (ECM)
components [7]. This complex process (dedifferentiation)
was observed in an in vivo experimental model of differ-
entiating spermatogonia, which generate germinal stem
cells [8], as well as in mammary luminal cells, which con-
vert to mammary stem cells upon the overexpression of* Correspondence: herminiamar@gmail.com
†Equal contributors
Laboratorio de Terapia Celular, Departamento de Bioquímica y Medicina
Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León,
León, Mexico
© 2015 Garza-Treviño et al.; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Sox9 and Slug [9]. Chronic inflammation promotes the
transition of epithelial cells to mesenchymal cells via the
expression of transforming growth factor-beta (TGF-β)
and tumor necrosis factor-alpha (TNF-α) [10,11].
A subpopulation of basal-like human mammary epithelial
cells that show spontaneous conversion into cancer stem
cell-like cells in vitro was recently reported [12]. It was also
demonstrated in a genetic model of intestinal tumor initi-
ation that epithelial non-stem cells can re-express stem cell
markers and be converted into tumor-initiating cells. This
phenomenon is strictly dependent on the degree of Wnt
activation and is only observed when Wnt signaling is
markedly elevated [13].Cancer stem cells
Evidence suggests that a small sub-population of tumor
cells, termed cancer stem cells (CSCs), are responsible
for propagating cancer in a highly efficient manner [14].
This malignant clonal population constitutes 0.1-10% of
all tumor cells [15] of which only some have the ability
to form tumors [16].
Compared to normal stem cells, CSC are thought to
show no restraint with respect to cell number (i.e., pro-
liferation); however, their slow rate of cycling plays a role
in resistance to treatment (chemotherapy and radiother-
apy) and tumor recurrence [17,18]. Also, the ability of
CSCs to initiate new tumors may be of critical importance
for metastatic colonization. In fact, the ability of a cancerentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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implantation and the ability of these cells to seed a
macroscopic growth following metastatic dissemin-
ation appear to be very similar processes, leading to
the notion that metastasis-forming ability is limited to
CSCs [3,19].
Recently, studies have shown that growth factors such
as epidermal growth factor (EGF), insulin-like growth
factor-1 receptor (IGF-IR), fibroblast growth factor-2
(FGF-2), vascular endothelial growth factor (VEGF) or
cytokines (TGF-β, TNF-α, IL-6) among others produced
by a microenvironment can revert differentiated cells to
a more stem cell – like state. Many studies have suggested
that the EGF signaling pathway regulates intestinal epithe-
lial cell and stem/progenitor cell growth and differenti-
ation [20]. However, there is little knowledge concerning
the role of growth factors in mediating proliferation and
self-renewal of colon CSC.
Properties of cancer stem cells
The properties of CSCs include infinite self-renewal
potential and the capacity to differentiate into the diverse
populations of cells that comprise a tumor.
– Self-renewal refers to the ability to form new stem
cells with an identical and intact potential for
proliferation, expansion, and differentiation, thus
maintaining the stem cell pool. Self-renewal
mechanisms that allow stem cells to persist
consistently involve proto-oncogenic pathways,
such as the Wnt/β-catenin and Notch pathways.
Another regulator of self-renewal in the context of
embryogenesis is the sonic hedgehog (Hh) signaling
pathway (reported in multiple myeloma); however,
little is known about the role of this pathway in
adult stem cells and CSCs [21]. The preferential
expression of Hh in CSCs was first published in a
pancreatic cancer xenograft model [22], and
evidence that the Hh pathway is aberrantly activated
in a number of solid tumors, including colon cancer,
has also been published [23].
A variety of signals have been shown to promote the
self-renewal capacities of colon CSCs, including the
Wnt pathway and the prevention of β-catenin-
dependent transcription. In addition, DLL4 stimulates
Notch receptors on neighboring cells and, together
with β-catenin, directs an immature transcription
profile that promotes self-renewal. BMP4 is also
known to counteract this self-renewal activity of
CSCs by binding to BMP receptors, thereby interfering
with Wnt signaling and subsequently promoting
differentiation. Last, hepatocyte growth factor (HGF)
has been shown to maintain colon CSCs in a stem-cell
state and prevent differentiation [24].Homeostasis (i.e., CSC maintenance and
proliferation) of the intestinal epithelium is tightly
controlled and depends on the spatial organization
of signals that emanate from supportive
mesenchymal cells, the stromal environment, and
differentiated epithelial progeny, although it remains
unclear how these latter cells are integrated into the
organization of intestinal cancers [25].
Increased numbers of CSCs may occur in poorly
differentiated tumors (through asymmetric cell
division and damaged stem cells) as well as
advanced tumors where the tumor
microenvironment promotes EMT, resulting in CSC
expansion. Furthermore, activation of these
pathways in stem cells over the life span of an
organism may predispose these cells to neoplastic
transformation and homeostatic proliferation.
– Differentiation is defined as the ability to develop
into a heterogeneous progeny of cells, which
progressively diversifies and specializes according to
a hierarchical process, constantly replenishing the
tissue of short-lived, mature elements [26]. Recent
reports about colon cancer have suggested that
individual tumors, at the histopathological level, are
relatively undifferentiated and may contain higher
proportions of CSCs than their more differentiated
counterparts, which have a significantly worse
clinical prognosis [27,28].
– Homeostatic control is the ability to modulate
and balance differentiation and self-renewal [26].
Recently, it was shown that differentiated cells in the
intestinal epithelium reside in the intestinal crypts as
at least two types of stem cells leucine-rich repeat
containing G protein-coupled receptor 5 (Lgr5) and
B lymphoma Mo-MLV insertion region 1 homolog
(Bmi-1), which serve to maintain the regenerative
capacities of this tissue under homeostatic condi-
tions [29]. Lgr5 expressing cells are the more active
stem cell type and serve to maintain the regenerative
capacities of these tissues under homeostatic
conditions. In addition, Lgr5 expressing cells are
actively proliferating and extremely sensitive to
Rspo1-mediated Wnt stimulation and Dkk1-mediated
Wnt inhibition. In contrast, Bmi-1-expressing cells
are less affected by environmental stress (i.e., not
sensitive to Wnt modulation), normally quiescent and
are held in reserve for “special occasions”, in which
they give rise to progeny that clonally repopulate
multiple contiguous crypt-villus axes during
subsequent intestinal regeneration [30]. However, the
homeostasis of tumoral epithelial tissues is governed
by a complex program, which is controlled by
niche-dependent signals that involve the subepithelial
stroma (VEGF, platelet-derived growth factor, TGF-β,
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(Notch, Hedgedog), natural enteric flora, as well as
intracellular transcription factors and the activation of
signaling networks associated with the epithelium (i.e.,
Wnt-β-catenin). As previously reported, Wnt proteins
and the Notch pathway are crucial for maintaining
stem cell homeostasis, as these signals have the
potential to maintain the phenotype of CSCs in the
tumor mass [31]. However, the equilibrium that
regulates the growth and maintenance of tumors is
poorly understood.
CSC markers
The discovery of CSC antigens is not based on the over-
expression of typical tumor antigens but on the presence
of antigens on populations of cells that have stem cell-
like properties. However, it is important to note that
variable expression levels of antigens on CSCs and their
frequent co-expression on normal stem cells have made
CSC antigen distinction difficult [15]. CD133, CD44,
CD24, CDCP1, CXCR4, and CD26 have been identified
as colon CSC surface antigens, but it is not well defined
which are the best markers to identify a tumor stem cell
[32,33] due to the variability found among individuals
with the same tumor type [31]. A better understanding
of the origin of CSCs during carcinogenesis would aid in
the search for better markers [34].
Malignant transformation of colon cancer
Tumorigenesis occurs when cells acquire six hallmarks:
self-sufficiency in growth signaling, insensitivity to anti-
growth signaling, evasion of apoptosis, unlimited replica-
tive potential, sustained angiogenesis and tissue invasion.
An initial event of cancer involves genetic defects that
cause DNA instability activation followed by less tumor
suppressor gene or gatekeeper pathway. The idea that
the key tumorigenic mutations occur in a few cells that
can self-renew and reside in tissues in the long-term is a
major shift in thinking and has implications in the ability
of adenomas to progress to carcinoma, and finally, in treat-
ment failure [35,36].
Model of colon carcinogenesis
The model of carcinogenesis begins with an expression
increase in intracellular β-catenin in normal colon epi-
thelial tissue, which results in the prolonged activation of
the Wnt pathway, β-catenin stabilization, and C-terminal
binding protein 1 (CtBP1). In addition, APC inactivation
contributes to adenoma initiation as the first step. KRAS
activation and β-catenin nuclear localization act syn-
ergistically to promote the progression of adenoma to
carcinoma [37]. Also, the loss of p53 and the heterozy-
gosity of chromosome 18q [38] are frequently observed
in advanced colorectal cancer (only the TP53 mutationis generally believed to occur at the time of transition of
an adenoma to cancer). Mutations in the transforming
growth factor-beta receptor (TGFBR) and phosphatidy-
linositol 3-kinase (PIK3CA) genes are reported to be
factors involved in tumor progression [39]. In addition,
recent studies have indicated that the cellular origin of
CRC initiation might involve the normal stem cells of the
intestine, rather than progenitors or differentiated cells. It
has been hypothesized that transformed stem cells pro-
gress to intestinal adenomas (Figure 1).
Cancer stem cells and carcinogenesis
Cancer stem/progenitor cells and their progeny attain
more malignant phenotypes during primary cancer pro-
gression via three distinct pathways of genomic instability:
the chromosomal instability, microsatellite instability, and
CpG island methylator phenotype pathways [40]. How-
ever, carcinoma develops a decade after the appearance of
polyps. Without prophylactic colostomy, colon cancer ap-
pears in 100% of these patients [39].
The tumorigenic pathways cooperate to activate differ-
ent downstream signaling effectors leading to carcinogen-
esis, including PI3K/Akt/molecular target of rapamycin
(mTOR), nuclear factor-kappaB (NF-kB), mitogen-activated
protein kinases (MAPKs), Myc and polycomb group (PcG)
proteins, such as B lymphoma Mo-MLV insertion region 1
homolog (BMI-1). Cooperation between these signal trans-
duction elements, in turn, plays a critical role in the high
self-renewal ability, sustained proliferation, survival, inva-
sion and metastasis of cancer stem/progenitor cells and
their progeny [39,41-47].
During the transformation process, defects in the
DNA mismatch repair (MMR) system result in microsa-
tellites in the genome that are either longer or shorter
than those in the parent cell. This phenomenon is
termed microsatellite instability (MSI). These are present
in two copies in most individuals and are responsible for
15%–20% of colon cancer cases [48]. Inactivation of
MMR enzymes can occur either through the aberrant
methylation of promoter CpG islands in the MLH1 gene
or through point mutations in MMR family genes. The
majority of these inactivation events are due to the epi-
genetic silencing of MLH1 gene expression by promoter
hypermethylation [49-52]. Aberrant hypermethylation in-
volves the covalent attachment of a methyl group to the
5´ position of cytosine and takes place in repetitive CG
dinucleotides or CpG-rich stretches of DNA within the
promoter region, resulting in transcriptional silencing. In
addition, other secondary pathways that regulate cellular
proliferation, differentiation, senescence, and apoptosis
(RAS/RAF/MAPK) have been reported [27,39].
Crypt progenitors divide every 12–16 h, generating
approximately 300 cells per crypt each day [53]. The
committed transit-amplifying (TA) cells are responsible
Figure 1 Carcinogenesis of colon cancer. Progression of colon normal epithelium to invasive carcinoma goes through several stages. The
invasive carcinoma stage involves epithelial cells losing their polarity and detaching from the basement membrane altering cell-ECM interactions
and signaling networks producing changes in stem cells that generate cancer stem cells. Malignant phase of tumor growth can progress from
this stage to metastatic cancer, also involving invasion of tissue by feed blood vascular systems.
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limited number of cell divisions, after which they ter-
minally differentiate into either secretory (goblet, paneth
and enteroendocrine) cells or enterocytes. Their prolifer-
ation is balanced by apoptosis and cell shedding at the
other end of the epithelial conveyor belt, the tip of the
villus. However, in the tumor process, it is assumed that
CSCs originate from normal stem cells after the accu-
mulation of mutations, and growth-promoting signals
change the microenvironment or niche for CSCs under-
going uncontrolled proliferation [54,55]. In recent years,
CSCs have received intense interest as key tumor-initiating
cells that may also play an integral role in recurrence fol-
lowing chemotherapy, particularly because of their ability
to proliferate [56] and self-renew [57] after chemotherapy,
irradiation or both [58]. As a result, a number of mecha-
nisms for the chemoresistance of CSCs have been identi-
fied [59].
Chemoresistance
Treatment with CRC-based chemotherapeutic regimens
principally includes 5 fluorouracil (5FU), oxaliplatin and/
or leucovorin or 5-FU, leucovorin and irinotecan (FOL-
FIRI). However, drug failure occurs in 90% of metastatic
cancers and is attributed to therapeutic resistance, which
is associated with increased aerobic glycolysis, fatty
acid synthesis, and glutamine metabolism, resulting in
decreases in drug-induced apoptosis [60]. In addition,
drug efflux transporter proteins (or ABC transporters)are generally found to be overexpressed in drug-resistant
cancer cells [61].
Cancer stem cells and chemoresistance
Chemotherapeutic drugs display antitumor effects in part
by inducing oxidative damage, which increases glycolysis
and results in high levels of NADPH (an antioxidant), an
event that can be associated with cancer chemoresistance;
however, increased ATP can activate ABC transporters to
increase drug efflux [61] and upregulate HIF-1α signaling,
inducing hypoxia-associated drug resistance. Specifically,
HIF-1α induces the expression of genes that promote sur-
vival through anti-apoptotic signaling (survivin, Bcl-XL,
Mcl-1) or other survival mechanisms, such as autophagy by
BCL2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3)
or BCL2/adenovirus E1B 19 kDa protein-interacting
protein 3-like (BNIP3L) [62-65]. Also, HIF-1α expres-
sion decreases pro-apoptotic signaling by inducing the
expression of decoy receptors, such as DcR2, that compete
for pro-apoptotic signaling factors, such as tumor necrosis
factor-related apoptosis-inducing ligand, thereby decreas-
ing productive signaling through apoptosis-inducing re-
ceptors, including DR4 and DR5 [66-69]. This attenuation
of pro-apoptotic signaling allows cells to tolerate a higher
level of chemotherapeutic insult before inducing cellular
death pathways.
Signals of chemoresistance
Another mechanism of CSC drug resistance is the pref-
erential activation of pro-survival signaling. For example,
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marker for CSCs in a variety of cancers. The binding of
CD44 by HA can lead to the association of CD44 with
epidermal growth factor receptor (EGFR) [63,64]. This
association activates MAP kinase and other cellular sig-
naling pathways, promoting cell survival in response to
antineoplasic treatments, such as cisplatin, methotrex-
ate, and adriamycin [70]. Furthermore, the HA-CD44
interaction activates EGFR-elicited cellular signaling
pathways without engagement of the ligand EGF [70-72],
which leads to resistance to targeted anti-EGFR ther-
apy [71].
Another signaling mechanism involves CD47. CD47 is
a widely expressed transmembrane protein, a receptor
for thrombospondin family members, and the ligand for
signal regulatory protein alpha (SIRPα). The CD47/SIRPα
interaction has been attributed as a mechanism that pro-
vides the cell with an anti-phagocytic signal. Tumor cells
express high levels of CD47 to avoid phagocytosis by
tumor-associated macrophages, and CD47 expression has
been shown to be required for the survival, growth and
metastasis of hematopoietic and solid tumors [72].
Finally, the failure of conventional treatment regimens,
particularly chemotherapy [73,74] and radiotherapy [75],
can be attributed to CSCs. In fact, CSCs can be segre-
gated from a cell population by selecting for cells that
exhibit resistance to standard cancer treatments [76].
New strategies are being sought to address this problem,
including a chemotherapy response assay that evaluates
the chemosensitivity of a tissue sample (in vitro) and the
design of compounds against CSCs.
Perspectives on treatment
Recently several compounds and drugs have been dis-
covered selectively against CSC [77]. Some of these are
microbe-derived and plant-derived biomolecules [78,79],
small molecule inhibitors that target key components of
the intrinsic signaling pathways of CSCs, some classical
drugs, such as metformin, tranilast, and thioridazine
[77], monoclonal antibodies (mAbs) and antibody con-
structs that are directed against CSC-specific cell surface
molecules, such as the CD44, CD47, EpCAM, CD123,
GD2, Lgr5, IGF-IR, Dll4 and FZD receptors [15,80],
or antibody derivatives. Technologies such as antibody
PEGylation [81] polysialylation [82] and albumin can
be used to engineer a longer blood half-life for use
against target signaling pathways and/or molecules that
selective operate in CSCs, some of which are also capable
of killing subpopulations of cancer cells that do not
display CSC properties. Therapeutic approaches with
mAbs [83-90], antibody constructs and novel thera-
peutic strategies against colon CSCs [91,92] are sum-
marized in Table 1, and some of these methods are
reviewed in detail below.Antibodies against cancer stem cells
Colon CSCs that are resistant to 5FU or oxaliplatin can
be sensitized with an interleukin-4 blocking antibody.
The autocrine stimulation of interleukin-4 receptors on
CSCs has been suggested to contribute to their stem-
ness, including their drug-resistant phenotype [76,93].
Another study demonstrated that the anti-EREG anti-
body (epiregulin, epidermal growth factor family) is effi-
cacious against tumor metastasis [94]. This antibody
showed only moderate activity against established xeno-
graft tumors in mice NOG (NOD/Shi-scid/IL-2Rcnull)
but exhibited a stronger efficacy in a metastatic model
tested in this study, suggesting that the anti-EREG anti-
body is efficacious in the early stage of cancer develop-
ment when cancers are rich in CSCs [94].
Other authors have reported the use of antibody con-
structs that target CSCs, which are more effective when
combined with conventional cytostatic drugs [77,88].
Combinations or cocktails of antibodies against bulk
tumor targets and CSC targets can sometimes destroy
the whole tumor as well as the resilient CSC population,
preventing relapse [95]. Also, the design of bi-specific
antibodies that recognize both CSC markers (which are
co-expressed on normal stem cells) and tumor antigens
could be used as a novel treatment to increase the speci-
ficity of CSC targeting [96].
Nanotechnology and cancer stem cells
Today, nanotechnology is encountered in many aspects
of our daily lives. The growing field of biotechnology
requires new tools that can easily interact with proteins
in even smaller sizes. Nanonization can be applied to
drugs for pharmaceutical use as a drug delivery system,
resulting in the effective and selective delivery of treat-
ment against tumor cells [97].
Drug delivery systems can be optimized with respect
to drug extrusion, low aqueous solubility and stability,
and high nonspecific toxicity using nanocarriers, such as
nanoparticles (NPs), liposomes, micelles, nanotubes and
nanogels, which have high penetrability. For example,
polymeric micelles with a core-shell structure can be
formed by the self-aggregation of polymeric amphiphile
for the delivery of cytotoxic agents after intravenous
administration in solid tumors providing a significant
advantage against tumor by increased the enhanced
permeability and retention effect of the cytotoxic com-
pounds [97]. A novel micelle formulation of oxaliplatin
encapsulated in a chitosan vesicle (CSO-SA/OXA mi-
celles) [92] shows an excellent internalization ability that
targets the tumor cell nucleus and increases the oxalipla-
tin concentration in tumor cells, which was shown to
eliminate CSCs in vitro and in vivo.
In another example, solid lipid nanoparticles (SLNs)
were utilized for the release of 5-FU inside the colonic
Table 1 Monoclonal antibodies and nanocarriers against human colon cancer stem cells
Target Compound Class Status Reference
anti-EpCAM/anti-CD3 MT110 (solitomab) BITE; human recombinant single chain
bispecific bifunctional mAb construct
Preclinical, in vitro, xenograft






Triomab; recombinant chimeric two half
antibody, each with one light and one
heavy chain from mouse IgG2a and rat
IgG2b isotypes. Bispecific, trifunctional
mAb construct
Phase I–III clinical studies [85]
anti-IGF-IR AVE1642 Humanized recombinant IgG1 mAb,
derived from mouse anti-IGF-IR
IgG1mAb EM164
Preclinical, xenograft mice [78]





Humanized IgG2 mAb Preclinical, xenograft mice
Phase I clinical studies,
combination with drugs
[79,83]
anti-Frizzled (1, 2, 5, 7, 8) OMP-18R5 (vanticumab) Humanized recombinant IgG2 mAb Preclinical, xenograft mice [80,86]
Drug efflux protein
multidrug resistance 1 (MDR1)
Lipid nanocarriers PEI-lipid nano complex with an
MDR1-targeting siRNA (siMDR1)
Human colon CSC (CD133+
enriched cell population)
[84]
Cancer stem-like cells (CSLCs)
that are resistant to conventional
chemotherapy and the bulk
cancer cells
CSO-SA/OXA micelles Micelle formulation of oxaliplatin
(OXA) encapsulated in chitosan
vesicle
In vitro (HT29 and SW620
line cellular [CD133+/CD24+])
[87]
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ever, these SLNs have not been evaluated in an in vivo
model to date [98]. The uptake of nanovehicles may
occur via endocytosis, in which the free drug is internal-
ized into cancer cells by molecular diffusion. Using
drug-loaded nanovehicles, the drug can be efficiently de-
livered via penetration of the cell membrane, especially
in chemoresistant tumor cells.
Liu C. has described a method by which chemotherapy
resistance in colon CSC can be overcome through the
siRNA-mediated knockdown of the drug efflux protein
MDR1, which often is overexpressed in CSCs. Utilizing a
moderate-throughput approach, the authors generated
libraries of lipid nanocarriers composed of varying ratios
of cationic polyethylenimine (PEI1200), polyethylene gly-
col (PEG) and a biodegradable lipid crosslinker such as
1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA).
The electrostatic complexes formed by mixing with siRNA
were screened for knockdown efficiency, and the opti-
mized nanocarrier formulations were found to achieve
>90% silencing. It has also been reported that treatment of
colon CSCs with lipid nanocarriers containing MDR1-
directed siRNA leads to efficient MDR1 knockdown and
sensitizes cells to subsequent paclitaxel treatment tested
in an in vitro model using CHOK1 cells [89].
In vitro assays have shown that nickel zinc ferrite
nanoparticles produce cytotoxicity in epithelial cancer
cells [99], and silver nanoparticles have been demon-
strated to induce apoptosis in human colon cancer cells
(HCT-116) dependent on the p53 expression [100]. Silvernanoparticles can be dissolved in solution, which prevents
their agglomeration, or entrapped in a matrix. These kinds
of particles represent interesting candidates for research
as broad-spectrum bactericidal and virucidal compounds
due to their effectiveness at small doses as well as their
minimal toxicity and side effects [94]. Thus, the admi-
nistration of silver nanoparticles (Table 1) during chemo-
therapy treatment in cancer patients could protect against
the recurrent infections caused by chemotherapy agents.
Nonetheless, conclusive safety has not been extensively
demonstrated in animal models, and therefore, additional
testing of silver nanoparticles is required before they can
be used in clinical applications.
Conclusion
A better understanding of how tumor-initiating cells,
such as CSCs, escape chemotherapy, the establishment
of appropriate biomarkers, and the definition of novel
clinical endpoints for monitoring the efficacy of com-
bined and multimodal therapeutic strategies will be a
challenge to improving future colon cancer treatment.
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